Stockscreener 앱 받기
161.69
3.94%
-6.64
시장 영업 전:
165.99
4.30
+2.66%
전일 마감가:
$168.33
열려 있는:
$169.69
하루 거래량:
984.01K
Relative Volume:
1.21
시가총액:
$12.48B
수익:
$8.27B
순이익/손실:
$173.28M
주가수익비율:
74.47
EPS:
2.1712
순현금흐름:
$785.90M
1주 성능:
-5.08%
1개월 성능:
-1.92%
6개월 성능:
+47.50%
1년 성능:
-15.09%
1일 변동 폭
$161.14
$177.67
1주일 범위
$160.41
$177.67
52주 변동 폭
$66.57
$203.91
Icon Plc Stock (ICLR) Company Profile
Compare ICLR vs TMO, DHR, NTRA, A, WAT
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ICLR
Icon Plc
|
161.69 | 13.30B | 8.27B | 173.28M | 785.90M | 2.1712 |
TMO
Thermo Fisher Scientific Inc
|
656.58 | 241.26B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
215.61 | 150.48B | 24.78B | 3.68B | 5.29B | 5.1743 |
NTRA
Natera Inc
|
400.65 | 59.47B | 2.50B | -226.32M | 71.51M | -1.6412 |
A
Agilent Technologies Inc
|
169.33 | 48.71B | 7.23B | 1.41B | 1.09B | 4.979 |
WAT
Waters Corp
|
436.43 | 42.59B | 3.77B | 449.25M | 240.68M | 7.8556 |
Icon Plc Stock (ICLR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-26 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2026-02-23 | 업그레이드 | Jefferies | Hold → Buy |
| 2026-02-18 | 업그레이드 | TD Cowen | Hold → Buy |
| 2026-02-17 | 다운그레이드 | Rothschild & Co Redburn | Buy → Neutral |
| 2026-02-12 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2026-02-12 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2026-01-08 | 다운그레이드 | Truist | Buy → Hold |
| 2025-12-15 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2025-11-13 | 개시 | BMO Capital Markets | Market Perform |
| 2025-09-09 | 다운그레이드 | Jefferies | Buy → Hold |
| 2025-09-03 | 업그레이드 | Rothschild & Co Redburn | Neutral → Buy |
| 2025-08-21 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2025-07-24 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2025-04-29 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2025-04-14 | 다운그레이드 | TD Cowen | Buy → Hold |
| 2025-04-10 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2025-03-21 | 다운그레이드 | Goldman | Buy → Neutral |
| 2025-01-07 | 개시 | RBC Capital Mkts | Outperform |
| 2024-10-24 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2024-10-14 | 개시 | Redburn Atlantic | Neutral |
| 2024-09-18 | 개시 | Leerink Partners | Outperform |
| 2024-06-06 | 개시 | Goldman | Buy |
| 2023-12-15 | 개시 | Truist | Buy |
| 2023-09-13 | 개시 | TD Cowen | Outperform |
| 2023-01-17 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2023-01-13 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2022-11-09 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2022-09-07 | 개시 | UBS | Buy |
| 2022-08-25 | 개시 | Credit Suisse | Neutral |
| 2022-05-24 | 개시 | Guggenheim | Buy |
| 2022-04-25 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2022-04-12 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2021-09-27 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2021-08-05 | 재개 | Credit Suisse | Outperform |
| 2021-07-23 | 업그레이드 | Citigroup | Neutral → Buy |
| 2021-07-14 | 개시 | Citigroup | Neutral |
| 2021-04-13 | 재개 | BofA Securities | Neutral |
| 2021-04-01 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2021-03-08 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2021-03-03 | 개시 | Barclays | Equal Weight |
| 2021-03-01 | 업그레이드 | UBS | Neutral → Buy |
| 2021-02-26 | 업그레이드 | Truist | Hold → Buy |
| 2020-07-24 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2020-04-20 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2020-03-26 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2020-03-02 | 개시 | Deutsche Bank | Hold |
| 2020-01-27 | 다운그레이드 | SunTrust | Buy → Hold |
| 2020-01-08 | 개시 | Wells Fargo | Equal Weight |
| 2020-01-07 | 개시 | Citigroup | Neutral |
| 2019-09-23 | 다운그레이드 | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2019-07-26 | 업그레이드 | UBS | Sell → Neutral |
| 2019-01-25 | 업그레이드 | Mizuho | Neutral → Buy |
| 2018-10-26 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2018-10-09 | 개시 | UBS | Sell |
| 2018-04-03 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2018-02-15 | 재확인 | Mizuho | Neutral |
| 2018-01-19 | 개시 | Evercore ISI | Outperform |
| 2017-10-27 | 재확인 | Barclays | Equal Weight |
| 2017-09-11 | 개시 | BofA/Merrill | Buy |
| 2017-07-31 | 업그레이드 | SunTrust | Hold → Buy |
| 2017-07-27 | 재확인 | Mizuho | Neutral |
| 2017-06-29 | 업그레이드 | Jefferies | Hold → Buy |
모두보기
Icon Plc 주식(ICLR)의 최신 뉴스
Hybrid Clinical Research Associate Job at ICON | Apply Online Here - BioTecNika
UBS Restarts Coverage of Icon PLC (ICLR) with Neutral Rating and $195 Price Target - GuruFocus
Hybrid Clinical Research Job Opening at ICON plc | Apply Online Here - BioTecNika
A Look at Icon PLC (ICLR) After 6.1% Gain -- GF Value $205.79 vs Price $173.90 - GuruFocus
ICON Plc (ICLR) Rises as Investors Appear to Lean on Backlog, Guidance, and Recent Filings - Moomoo
ICON plc (ICLR) rises as investors appear to lean on backlog, guidance, and recent filings - Quiver Quantitative
ICON Public Limited Company’s (ICLR) Shrinking Moat Warranted an Early Departure - Yahoo Finance
Icon PLC (ICLR) Stock Up 3.3% and Still Undervalued -- GF Score: 95/100 - gurufocus.com
Rare Disease Contract Research Organization (CRO) Market Outlook 2026-2030: Investment Trends, Strategic Profiles and Revenue Share Outlook - GlobeNewswire Inc.
ICON plc stock edges higher after analyst updates and steady Q2 figures - AD HOC NEWS
Icon PLC (ICLR) Stock Down 3.3% -- Now Undervalued? GF Score: 96/100 - GuruFocus
Citi Maintains Icon PLC(ICLR.US) With Hold Rating, Raises Target Price to $175 - Moomoo
ICLR Maintained by Citigroup -- Price Target Lowered to $175 - GuruFocus
Strategic Sale: DR JOHN CLIMAX Decides To Exercise Options Worth $204K At Icon - Benzinga
ICON PLC Director Eugene McCague Exercises Stock Options and Sells Shares on September 17, 2026 - kalkinemedia.com
S&P 500 Futures Rise in Premarket Trading; Xenon Pharmaceuticals, Icon PLC Lag - Barron's
Icon (ICLR) insider sells 5,005 shares after exercising options - Stock Titan
Director at ICON (ICLR) unloads stock right after exercising options - Stock Titan
Director at ICON (NASDAQ: ICLR) exercises options, then sells 5,005 shares - Stock Titan
Truist Financial Maintains Icon PLC(ICLR.US) With Buy Rating - Moomoo
ICON PLC (NASDAQ: ICLR) director plans 569,625 stock sale - Stock Titan
ICON (NASDAQ: ICLR) director plans to sell thousands of shares in 2026 - Stock Titan
ICON plc Q2 2026 Earnings: EPS Narrowly Misses Estimate as Stock Edges LowerProduct Revenue Analysis - careplusvn.com
ICON plc (NASDAQ: ICLR) director plans $876K sale after $138K trade - Stock Titan
ICON plcOrdinary Shares (Nasdaq:ICLR) Detailed Stock Data - The Chronicle-Journal
ICON plc (ICLR) Stock Analysis: Unpacking a 9.6% Potential Upside in the Healthcare Sector - DirectorsTalk Interviews
ICON plc Stock Price: ICLR Stock Chart, Market Cap & News Today - CoinGecko
A Look at Icon PLC (ICLR) After 3.9% Gain -- GF Value $207.68 vs Price $165.69 - GuruFocus
ICON PLC (NASDAQ: ICLR) Releases Unaudited Interim Financial Statements in September 9 Filing - kalkinemedia.com
ICON taps Anthropic and Microsoft as it puts clinical-trial agents into production - R&D World
[6-K] ICON PLC Current Report (Foreign Issuer) - Stock Titan
Is Icon PLC (ICLR) a Bargain After 4.1% Drop? GF Value Says Unde - GuruFocus
ICON plc (ICLR) Stock Report: Evaluating a 12.56% Potential Upside Amidst Healthcare Sector Expansion - DirectorsTalk Interviews
Long term debt to total equity ratio of ICON Plc – HAM:IJF - TradingView
Icon plc stock holds steady as Q2 2026 results support full-year guidance - ad-hoc-news.de
ICON Plc (ICLR) Stock Analysis: Exploring Growth Potential With A 9.14% Upside - DirectorsTalk Interviews
How ICON’s Mixed Q1 Earnings and Reaffirmed 2026 Outlook Could Impact ICON (ICLR) Investors - sahmcapital.com
Icon PLC (ICLR) Up 2.5% Since Last Earnings Report: Can It Continue? - Yahoo Finance
Icon (ICLR) Stock Forecast and Price Target 2026 $ICLR - MarketBeat
ICON plc (ICLR) Stock Analysis: Navigating Growth in Diagnostics & Research with a 7.74% Upside - DirectorsTalk Interviews
ICON Releases 2025 ICON Cares Report, Highlighting Progress in Patient Impact, Innovation and Sustainability - BioSpace
ICON plc (ICLR) posts top-1% ESG score and 73% emissions cut - Stock Titan
A Look at Icon PLC (ICLR) After 3.2% Gain -- GF Value $208.22 vs Price $172.49 - GuruFocus
ETFs Investing in ICON Plc Stocks - TradingView
ICON plc (NASDAQ: ICLR) swaps secured loans for $2.15B in new notes - Stock Titan
White & Case advises ICON on its US$2.15 billion notes offering and related secured debt refinancing - White & Case LLP
6-K: Icon PLC | 6-K: Report of foreign private issuer (related to financial reporting) - Moomoo
Icon PLC (ICLR) Shares Surge 3.9% -- What GF Score of 93 Tells I - GuruFocus
ICON plc (ICLR) Stock Analysis: Strong Buy Ratings and 13.74% Potential Upside Highlight Investment Appeal - DirectorsTalk Interviews
Icon CEO awarded $3.7m in shares as company emerges from turmoil - Irish Independent
Does ICON’s Shift to an Unsecured Capital Structure Reshape the Bull Case for ICLR? - Sahm
Icon Plc (ICLR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Icon Plc 주식 (ICLR) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| CLIMAX JOHN DR | Director |
Sep 16 '26 |
Sale |
175.00 |
5,005 |
875,875 |
2,087 |
| McCague Eugene Pacelli | Director |
Sep 17 '26 |
Option Exercise |
125.74 |
3,255 |
409,284 |
7,066 |
| McCague Eugene Pacelli | Director |
Sep 17 '26 |
Sale |
175.00 |
3,255 |
569,625 |
3,811 |
| Murphy Ronan Martin | Director |
Sep 17 '26 |
Option Exercise |
125.74 |
5,005 |
629,329 |
8,852 |
| Murphy Ronan Martin | Director |
Sep 17 '26 |
Sale |
175.00 |
5,005 |
875,875 |
3,847 |
0.99%
0.56%
자본화:
|
볼륨(24시간):